Biological E. Secures Full WHO Approval for Novel Polio Vaccine, Boosting Global Outbreak Response
Hyderabad-based pharmaceutical and biologics company, Biological E. Ltd (BE), has achieved a significant milestone in the fight against polio. The World Health Organization (WHO) has granted Phase II pre-qualification (PQ) to BE’s novel oral polio vaccine type 2 (nOPV2), enabling the company to manage the entire vaccine manufacturing process independently. This upgrade, from the Phase I approval received in June 2024, signifies a major step towards a more resilient and responsive global polio vaccine supply.
What Does Full WHO Approval Mean?
The Phase II PQ covers both the drug substance and drug product manufactured at Biological E.’s integrated facility. This means BE can now independently produce the vaccine from start to finish, streamlining production and ensuring a consistent, reliable supply. Previously, the company relied on external sources for certain components.
A Critical Vaccine for Outbreak Control
nOPV2 is specifically designed to control circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks. According to BE, they have already manufactured and delivered 700 million doses of the vaccine to countries actively combating these outbreaks. Globally, nOPV2 has been deployed in over a billion doses.
“When polio outbreaks occur, response time and vaccine availability determine how quickly transmission can be stopped,” explains Mahima Datla, Managing Director of Biological E. Ltd. “nOPV2 has already been deployed in over a billion doses globally because We see designed specifically for outbreak control with improved genetic stability.”
Strengthening Global Vaccine Security
The WHO pre-qualification is crucial for ensuring that vaccines meet international quality, safety and efficacy standards. This allows organizations like UNICEF and the Pan American Health Organization to procure the vaccine for use in global immunization programs. Having an integrated, WHO-qualified manufacturing site like BE’s is vital for bolstering global outbreak response readiness.
Datla emphasizes the importance of this advancement: “With Phase II WHO Pre-Qualification enabling full end-to-end manufacturing at our facilities, global supply becomes more resilient and more responsive. That matters because every delay in outbreak response carries real risk for children, and communities.”
The Future of Polio Eradication and Vaccine Manufacturing in India
Biological E.’s achievement highlights the growing capabilities of Indian pharmaceutical companies in vaccine development and manufacturing. India is increasingly becoming a global hub for vaccine production, playing a critical role in ensuring equitable access to essential immunizations worldwide.
Expanding Vaccine Coverage and Innovation
Beyond polio, Biological E. Is also focused on expanding its portfolio of vaccines. In November 2025, the company secured WHO pre-qualification for its 14-valent Pneumococcal Conjugate Vaccine (PCV), PNEUBEVAX 14®, offering the broadest coverage of any paediatric PCV currently available in India. This demonstrates a commitment to addressing a wider range of infectious diseases.
The Role of Novel Oral Polio Vaccines
The development and deployment of nOPV2 represent a significant advancement in polio eradication efforts. Traditional oral polio vaccines (OPV) can, in rare cases, revert to a form of the virus that can cause paralysis. NOPV2 is genetically more stable, reducing this risk even as still providing effective protection against the virus.
Frequently Asked Questions (FAQ)
- What is nOPV2? nOPV2 is a novel oral polio vaccine type 2 used to control outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2).
- What does WHO pre-qualification mean? It means the vaccine meets international standards for quality, safety, and efficacy, allowing for procurement by UN agencies and global immunization initiatives.
- How many doses of nOPV2 has Biological E. Produced? Biological E. Has already produced and delivered 700 million doses.
- Why is integrated manufacturing important? It ensures a more resilient and responsive vaccine supply, reducing delays during outbreak responses.
Pro Tip: Staying informed about global health initiatives and vaccine developments is crucial for understanding the ongoing efforts to protect communities from preventable diseases.
Learn more about Biological E. Limited and their commitment to global health: https://www.biologicale.com/
What are your thoughts on the future of polio eradication? Share your comments below!